Irenic Capital Management LP: THERAVANCE BIOPHARMA INC (TBPH): Quarterly 13F Position History
As of Q1 2026, Irenic Capital Management LP reported 2,760,948 shares of THERAVANCE BIOPHARMA INC (TBPH), worth $44.8M and representing 4.1% of its 13F equity book. The position first appeared in Q4 2022 and has been disclosed across 14 13F-HR filings in Pactolio's tracked window.
- 2,760,948Shares Held (Latest Filing)
- $44.8MReported Market Value (Latest Filing)
- 4.1%Portfolio Weight (% of 13F Equity Book)
- 0Quarter-over-Quarter Share Change
- -$6.8MQuarter-over-Quarter Value Change
- 2,764,048Peak Reported Shares (Historical)
Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 14 quarter s
| Quarter | Shares | QoQ Share Change | Share Change (%) | Market Value | Weight | Implied Price |
|---|---|---|---|---|---|---|
| Q1 2026 | 2,760,948 | 0 | — | $44.8M | 4.1% | $16.2 |
| Q4 2025 | 2,760,948 | 0 | — | $51.7M | 6.8% | $18.7 |
| Q3 2025 | 2,760,948 | 0 | — | $40.3M | 7.9% | $14.6 |
| Q2 2025 | 2,760,948 | 0 | — | $30.5M | 6.7% | $11.0 |
| Q1 2025 | 2,760,948 | 0 | — | $24.7M | 3.7% | $8.9 |
| Q4 2024 | 2,760,948 | 0 | — | $26.0M | 4.0% | $9.4 |
| Q3 2024 | 2,760,948 | 0 | — | $22.3M | 3.9% | $8.1 |
| Q2 2024 | 2,760,948 | 0 | — | $23.4M | 5.7% | $8.5 |
| Q1 2024 | 2,760,948 | 0 | — | $24.8M | 6.3% | $9.0 |
| Q4 2023 | 2,760,948 | 0 | — | $31.0M | 6.7% | $11.2 |
| Q3 2023 | 2,760,948 | 0 | — | $23.8M | 7.3% | $8.6 |
| Q2 2023 | 2,760,948 | 3,100 | -0.1% | $28.6M | 9.8% | $10.3 |
| Q1 2023 | 2,764,048 | +1,063,111 | +62.5% | $30.0M | 12.5% | $10.8 |
| Q4 2022 | 1,700,937 | — | — | $19.1M | 10.1% | $11.2 |
Methodology & FAQ
How This Position History Is Sourced
Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares — a quarter-end mark, not the manager's cost basis. See the full methodology document for the normalization rules.
When did Irenic Capital Management LP first disclose a TBPH position in 13F-HR filings?
Irenic Capital Management LP first reported THERAVANCE BIOPHARMA INC (TBPH) on its 13F-HR filing for the period ending 2022-12-31 (Q4 2022). The position has appeared on 14 reported quarters within Pactolio's tracked window.
What was Irenic Capital Management LP's most recent quarter-over-quarter share-count change in TBPH?
Irenic Capital Management LP held the same 2,760,948 shares of TBPH between Q4 2025 and Q1 2026 — the reported share count was unchanged quarter-over-quarter.
Does the implied price-per-share represent Irenic Capital Management LP's cost basis in TBPH?
No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.